

Exhibit # 1



6024 SW Jean rd. Bldg. B
Lake Oswego, OR 97035
503-675-2187
503-699-2785 (fax)

January 2, 2001

FEDERAL COMMUNICATIONS COMMISSION
Experimental Radio Service
P.O. Box 358320
Pittsburgh, PA 15251-5320

To the Experimental Licensing Branch,

I am submitting this narrative statement in response to line item 10 of form 442.


Biotronik, Inc. seeks experimental licensing for use of the broadband PCS service in the frequency range of 1850 - 1990MHz. All performance requirements defined by the FCC in Part 24 Subpart E (Broadband PCS) will be met with our experimental systems during this development effort. Part of this development effort will include FTA and FCC conformance testing for final submission.

Biotronik is a leading manufacturer of implantable pacemaker and defibrillator devices, and wishes to initiate evaluation and development of wireless communications from these implantable devices directly to the patient's physician.

Wireless transmission of data is the key to Biotronik's new medical service called Home Monitoring. By automatically transmitting a patient's critical cardiac information wirelessly, a physician can manage each patient's condition without a hospital visit.

Detailed Description of System Operation

Biotronik monitoring communications are provided in two distinct data transmission steps. A block diagram of the transmission path is shown below.



- ① During the year 2000, Biotronik requested and was granted an experimental license for a short distance, ultralow power RF transmitter at 403.65MHz carrier frequency (File # 0020-EX-PL-2000, call sign WB2XGF). This transmitter circuitry is integrated within the pacemaker electronics. Data is transmitted at a distance of two to three meters to a bedside receiver, which is interfaced to a cellular telephone module.
- ② The patient is equipped with a receiver centered at 403.65MHz with a 300KHz bandwidth to accept the incoming data. The receiver is interfaced to a 1900MHz GSM cellular telephone module manufactured by Wavecom, Inc. This module provides a means for transmission of data via cellular telephone service to the Biotronik service center. Specialized analysts at the Biotronik Service Center receive incoming data and generate a summarized report, which is forwarded to the physician.

Scope of Experimentation

The experimental license is being sought to allow for a clinical study to be performed. The protocol for this study is part of a requirement by the Food and Drug Administration (FDA) and is termed an Investigational Device Exemption (IDE) study.

Biotronik plans to perform this study with a maximum of 100 experimental systems under clinical evaluation. Each transmitter/receiver will provide less than or equal to 10 transmissions per day. The duration of each transmission is approximately 70 milliseconds. Patient data from this transmission is then forwarded by the Wavecom cellular module using the digital Short Messaging System (SMS). Each digital transmission at 1900MHz is conducted in a matter of seconds. Not all 100 systems will be operational concurrently, but the entire study will have a duration of less than the 2 years allotted by the experimental license.

The implanted units are obviously mobile, as is the receiver and cellular telephone system. Sites for the study have yet to be determined, but will be in various clinical locations throughout the United States. The exact geographical coordinates during operation is presently unknown (requirement of line item 5c). Such information can be provided to the FCC once clinical sites have been established.

At the conclusion of the experimental phase, application to the Food and Drug Administration will be made with the summary results of the study. Formal license application for the Biotronik cellular communication system will also be filed with the FCC.

If there are any further questions regarding the specific objectives sought with this experimental license, please contact me at (503) 675-2187 or E-mail: maj@bioregon.com.

Sincerely,



Mark Johnson
New Business Development Manager
Biotronik, Inc.